Zildaglip M 500mg/50mg Tablet

The combined action of these agents provides complementary mechanisms to achieve better glycemic control compared to monotherapy. Zildaglip M is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters in adult patients inadequately controlled on either agent alone. It is important to monitor renal function prior to and during treatment due to Metformin’s renal clearance and risk of lactic acidosis in patients with impaired kidney function.

Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Vildagliptin is generally well tolerated with a low risk of hypoglycemia. Dose adjustments and contraindications should be carefully considered by healthcare professionals.